2 vials Save $70

Tirzepatide 20mg

Lyophilized research peptide

$137.49

AOD 9604 10mg

Lyophilized research peptide

$212.49

Research bundle · 2 vials

Tirzepatide 20mg + AOD 9604 10mg Research Bundle

USA Made, ≥99% Purity Per Compound

Separate retail vials: Tirzepatide 20mg; AOD 9604 10mg
USA manufactured in a Certified GMP California and Arizona laboratory.
≥99% purity target per compound with independent third-party HPLC, mass spectrometry, and batch-specific COAs

Combined retail value$349.98

Bundle saving−$70.00

$279.98 $349.98 Save $70

Each vial ships in its original retail format with its own batch COA

Dispatched from a US warehouse within 48 hours, tracked

Store at -20°C (Freeze) or 2–8°C (Refrigerated) protected from light

Disclaimer

For research purposes only. Not intended for human consumption, medical use, diagnosis, treatment, or prevention of disease.

Per-compound specifications

2 vials

Nothing in this bundle is co-formulated. Each vial keeps its own identity, purity target, and certificate, and is specified separately below.

Vial 01

Tirzepatide 20mg

Sequence

Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-Lys(AEEA-AEEA-γGlu-C20 diacid)-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2

CAS: 2023788-19-2
Molecular mass: 4,813.53 g/mol
Purity target: ≥99%
Form: Lyophilized Powder

Vial 02

AOD 9604 10mg

Sequences

Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe; Cys7–Cys14 disulfide bridge

CAS: 221231-10-3
Molecular mass: 1,815.1 g/mol
Purity target: ≥99%
Form: Lyophilized Powder

Form: 2 Separate Lyophilized Powders
Purity target: ≥99% per compound (3rd-Party HPLC Tested)
Origin: All Included Products: Synthesized, Formulated & Packaged in CA/AZ, USA
Storage: Store at -20°C (Freeze) or 2–8°C (Refrigerated) protected from light

What is the Tirzepatide 20mg + AOD 9604 10mg Research Bundle?

This two-vial research bundle combines Tirzepatide 20mg and AOD 9604 10mg. Tirzepatide is a lipidated 39-amino-acid peptide that activates both GIP and GLP-1 receptors in experimental systems. AOD 9604 is a synthetic 16-amino-acid growth-hormone fragment studied primarily in preclinical lipid-signaling models.

Together, the set supports controlled work across dual incretin-receptor signaling and preclinical lipid-metabolism pathways in higher-material laboratory workflows. Each retail product stays in its own lyophilized vial, so the bundle does not create a new formulation or establish a proven combined effect.

How It Works

Tirzepatide activates two incretin receptors: GIPR and GLP-1R support study of coordinated nutrient-responsive signaling, while lipidation supports albumin interaction.

AOD 9604 isolates a defined growth-hormone fragment: Preclinical models examine lipolysis, lipogenesis, and beta-3 adrenergic-receptor expression; a definitive direct target remains unresolved.

Separate vials protect experimental control: Study either retail product independently or compare their distinct signals without treating the bundle as one formulation.

Why Source from 321 Peptides?

Domestic accountability.

All included compounds are synthesized, manufactured, formulated, finished, and packaged in Certified GMP laboratory facilities in California and Arizona—never sourced from overseas or Mexico. That creates direct domestic supply-chain accountability from production through fulfillment.

Verification you can inspect.

Independent third-party HPLC evaluates each compound against its ≥99% purity target, while mass spectrometry confirms molecular identity. For each vial, the results are documented in one combined, batch-specific Certificate of Analysis report.

Protected in transit.

Every included product is freeze-dried to help preserve stability during storage and shipping. Rapid domestic fulfillment reduces unnecessary time and handling.

Lot history 6 released lots

Every batch released under each vial in this bundle, with the figure reported for each. Vials are shipped from current stock.

Compound	Lot	Reported	Purity	Net content	COA
Tirzepatide 20mg	TI-59207	2026-04-23	99.64%	20.04 mg	Pending
	TI-59784	2026-03-19	99.88%	20.06 mg	Pending
	TI-58630	2026-02-25	99.52%	20.02 mg	Pending
AOD 9604 10mg	AO-35679	2026-04-23	99.64%	10.00 mg	Pending
	AO-36256	2026-03-19	99.88%	10.01 mg	Pending
	AO-35102	2026-02-25	99.52%	10.08 mg	Pending

Frequently Asked Questions

What comes in the Tirzepatide 20mg + AOD 9604 10mg bundle?

The bundle includes one Tirzepatide 20mg vial and one AOD 9604 10mg vial. Each product arrives separately in lyophilized form with batch-specific COA documentation.

What research pathways are represented in this bundle?

The bundle spans dual incretin-receptor signaling and preclinical lipid-metabolism pathways in higher-material laboratory workflows. Each compound retains a distinct experimental profile, and the bundle does not establish clinical synergy.

Are these FDA-approved prescription products?

No. Some included active ingredients also appear in FDA-approved finished medicines, but the research vials in this bundle are not those approved products or substitutes. Every vial is supplied exclusively for controlled, non-clinical research.